Podcasts about Molecular diagnostics

In the second episode of our miniseries on infectious disease diagnostics, Jonathan is joined by molecular epidemiologist Rodney Rohde, Regents' Professor at Texas State University, USA. Together, they explore diagnostic innovations in the fight against antimicrobial resistance, gaps in zoonotic disease detection, and the persistent challenge of vaccine hesitancy. Timestamps: 00:00 – Introduction 01:45 – Breakthroughs in molecular diagnostics 08:30 – Diagnostic tools to combat superbugs 14:18 – Can bacteriophages replace antibiotics? 19:04 – Controlling rabies and hantavirus 28:33 – Diagnostic successes and failures from COVID-19 35:22 – How do we address vaccine hesitancy? 44:10 – Preparing for the next pandemic 47:03 – Rohde's three wishes for healthcare

Send us a textDr. Anastasia Liapis, Ph.D. is Global Head of Innovation & New Business Creation, HP Health Solutions ( https://www.izb-online.de/en/companies/hp-health-solutions-germany-gmbh/ ), a division of HP ( https://www.hp.com/us-en/home.html ) , that develops technology specifically for the healthcare industry and reimagines healthcare tech for diagnostics and precision medicine of the future.Dr. Liapis' team leads innovation in diagnostics and health-tech, driving the development and commercialization of ultrafast PCR and microfluidic-based diagnostic platforms, as well as focuses on early-stage technology development, partnerships, and business strategy, ensuring breakthrough innovations translate into real-world impact.Previously, Dr. Liapis served as Vice President of Strategic Marketing & Partnerships at GNA Biosolutions GmbH, a molecular diagnostics start up that was acquired by HP, and she played a pivotal role in enhancing the organization's strategic vision, focusing on innovative solutions in the bioscience sector.Before taking her role at GNA Biosolutions, Dr. Liapis made significant contributions to various notable organizations such as TBWA, the healthcare agency creative collective, where she served as a Group Account Supervisor, and as of Vice President of Medical Affairs at Medical Dynamics, developing medical education programs and fostering key opinion leader (KOL) relationships.Dr. Liapis completed her doctoral training in Genetics at the Mount Sinai School of Biomedical Sciences and her post-doctoral fellowship in Immunology at the Skirball Institute of Biomolecular Medicine at NYU Langone. She earned both her Master's and Bachelor's degrees in Biology from Washington University in St. Louis.#AnastasiaLiapis #HPHealthSolutions #HP #HewlettPackard #Healthtech #Biosecurity #LifeSciences #FoodSafety #NucleicAcidAmplification #MolecularAssays #Biotechnology #Nanotechnology #GNABiosolutions #MolecularDiagnostics #Microfluidics #PolymeraseChainReaction #PCR #Bioscience #CarT #LysosomalStorageDisorders #BrandStrategy #ScientificWriting #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Season 2 of Absolute Gene-ius comes to a close with a look back at the topics and inspiring conversations that have defined the series. From exploring innovative uses of digital PCR to uncovering its synergy with other molecular tools, this season was packed with insights for scientists at all levels.Dive into the details as co-hosts Jordan Ruggieri and Christina Bouwens revisit memorable episodes, including using dPCR as a low-cost precursor to single-cell sequencing and its role in quantifying active mRNA in groundbreaking drug development. Hear from experts like Parker Wilson, Christian Cobaugh, and Raquel Munoz, who share how digital PCR is revolutionizing their workflows and complementing other tools like qPCR and NGS.Of course, it wouldn't be Absolute Gene-ius without a few puns! Stick around for some lighthearted banter as Jordan and Christina celebrate the season's success, share their favorite moments, and hint at what's coming in Season 3. Stay curious, and we'll see you next cycle!Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

In this TOGA podcast, we provide an overview of the treatment options for rare subtypes of oncogene driven NSCLC that are now readily identified in the MBS-reimbursed small gene panel including NTRK1, 2,3 and other rare mutations in NSCLC. The importance of testing all patients is discussed as well as what to do when resistance occurs. Associate Professor Steven Kao, Medical Oncologist from Chris O'Brien Lifehouse and Clinical Associate Professor Sydney Medical School, Faculty of Medicine and Health is joined by Professor Wendy Cooper, senior staff specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, Anatomical Clinical Stream Lead for NSW Health Pathology, a Clinical Professor at the University of Sydney and a Conjoint Professor at the University of Western Sydney and also Professor Ben Solomon head of the lung Medical Oncology Service and a Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division at Peter MacCallum Cancer Centre as well as a Founding Board member of TOGA.

In this episode of SEE HEAR FEEL, Christine J. Ko welcomes Dr. Gregory A. Hosler, president of the Dermatopathology Division of Sonic Healthcare USA. The conversation delves into his recent study on diagnostic discordance in dermatopathology, exploring its implications for patient management and highlighting the importance of ancillary testing and second opinions. Dr. Hosler also shares insights on emotional intelligence, emphasizing the significance of self-awareness and continuous improvement in pathology practice.00:00 Introduction and Guest Background01:54 Personal Anecdote and Career Journey02:31 New Role and Responsibilities03:38 Diagnostic Discordance Study07:20 Improving Diagnostic Practices10:55 Emotional Intelligence and Self-Reflection12:42 Final Thoughts and ConclusionGregory A. Hosler, MD, PhD is President of the Dermatopathology Division of Sonic Healthcare USA (SHUSA). Before taking this role, he was at ProPath, which joined SHUSA in 2021, and at ProPath, he served as partner, board member, and Director of Dermatopathology. He is a Clinical Professor in the Departments of Dermatology and Pathology at the University of Texas Southwestern (UTSW). He has held numerous leadership roles in local and national societies, including serving on the Executive Board for the American Society of Dermatopathology (ASDP, 2021-present), as President of the Texas Society of Pathologists (2019), President of the North Texas Society of Pathologists (2015), and President of the Educational Foundation of the TSP (2020).Dr. Hosler obtained his B.S.E. in Chemical Engineering at Princeton University and completed his medical degree and graduate work at UTSW in Molecular and Cellular Biology and Immunology (MD/PhD Medical Scientist Training Program). He completed his residency in Anatomic and Clinical Pathology at The Johns Hopkins Medical Institutions (JHMI), and his fellowship in dermatopathology, also at JHMI. Dr. Hosler is very involved in education, teaching at the fellowship, residency, and medical school levels. He is the Director of the ACGME-accredited Dermatopathology Fellowship Program at ProPath. He actively speaks, writes, and directs courses on dermatopathology. He is the editor and co-author of two dermatopathology textbooks - Molecular Diagnostics in Dermatology: practical applications of molecular testing for the diagnosis and management of the dermatology patient (Springer) and Diagnostic dermatopathology: a guide to ancillary tests beyond the H&E (JP Medical Publishers). He is also the author of the melanocytic chapter in Weedon's Skin Pathology (4th, 5th, and 6th Eds, Elsevier) and many peer-reviewed journal articles and reviews.

An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells. At the AACR Annual Meeting 2024 in San Diego, Peter Goodwin talked with Ajay Goel, PhD, AGAF, senior author of the study and Chair of the Molecular Diagnostics and Experimental Therapeutics in the Beckman Research Institute at City of Hope in Los Angeles.

Darrol Roberts, CEO of Hessian Labs, joins the For Your Health News podcast to discuss his journey into diagnostic technologies. Roberts shares his personal health challenges, the financial burden of cancer, and what diagnostic tools are most beneficial to patients. Join us for this conversation on the role that diagnostics plays in cancer care for all communities. Learn more about Hessian Labs and their work to improve the patient experience at each stage of their illness with accurate, non-invasive diagnostic and therapy monitoring tools: https://www.hessian-labs.com/Visit fyh.news for more health care information that empowers minoritized communities. Learn more about NMQF's Cancer Stage Shifting Initiative (CSSI): shiftcancer.org 00:00 Introductions 00:25 Why Focus on Diagnostics? 02:55 The Financial Burden of Cancer 04:13 The Challenges of Cancer Therapies 06:52 Molecular Diagnostics

Scientists continuously develop new assays to fill unmet diagnostic needs. While methods such as quantitative PCR have emerged as essential tools in molecular diagnostics, scientists developing and administering these assays still must overcome technical challenges. In this podcast series, The Scientist's Creative Services Team talks to experts about their experiences designing and implementing assays and protocols for future molecular diagnostics. In this episode, Deanna MacNeil from The Scientist's Creative Services Team spoke with Gregory Tsongalis, medical director for the Center for Clinical Genomics and Advanced Technology at Dartmouth Health, about the benefits of PCR-based DNA testing for HPV screening.   Welcome to Molecular Diagnostics: An Eye Toward the Future, a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Thermo Fisher Scientific, a world leader in serving science. Their mission is to enable customers to make the world healthier, cleaner, and safer. Whether their customers are accelerating life sciences research, solving complex analytical challenges, and improving clinical research workflows, Thermo Fisher Scientific is here to support them.

The development of medical treatments often requires use of human subjects, as well as human cells and body parts as models of human systems, to investigate mechanisms of action and to test therapeutics. Biotechnology has provided many successful therapies for previously intractable conditions, but also increasingly complex techniques that can alter what it means to be human and blur ethical lines. When we consider stem cells, cloning, gene editing, human-animal chimeras, organoids, embryoids and so-called synthetic embryos, what is ethical and what crosses the line of human dignity? Is any scientific endeavor justifiable because of a potential for cures, or are there ethical limits to efforts to heal or eliminate certain diseases all together? Do ethical alternatives exist that would benefit humanity without losing our ethical integrity?The Charlotte Lozier Institute has developed the Handbook of Nascent Human Beings to explain the science and to stimulate discussion on the ethics and moral permissibility of modern medicine and biotechnology. The place of this research in policy will also be discussed.David A. Prentice, Ph.D. is Vice President for Scientific Affairs at the Charlotte Lozier Institute. He is also Advisory Board Chair and a Founding Member for the Midwest Stem Cell Therapy Center, a unique comprehensive stem cell center in Kansas that he was instrumental in creating. In 2020, he was appointed by the Secretary of HHS to the federal Human Fetal Tissue Ethics Advisory Board. Dr. Prentice has almost 50 years' experience as a scientific researcher and professor, including previous service as a staff member at Los Alamos National Laboratory, senior fellow at the Family Research Council, Professor of Life Sciences at Indiana State University, Adjunct Professor of Medical and Molecular Genetics, Indiana University School of Medicine, and Adjunct Professor of Molecular Genetics at the John Paul II Institute, The Catholic University of America. He has provided scientific lectures, policy briefings and testimonies in 40 states and 21 countries, including before the U.S. House and Senate and numerous state legislatures, the U.S. National Academy of Sciences, the President's Council on Bioethics, European Parliament, British Parliament, Canadian Parliament, Australian Parliament, German Bundestag, French Senate, Swedish Parliament, the United Nations, and the Vatican.Tara Sander Lee, Ph.D., is Vice President and Director of Life Sciences at the Charlotte Lozier Institute. A scientist with over 20 years' experience in academic and clinical medicine with an emphasis on the cause of pediatric disease, Dr. Sander Lee earned a Ph.D. in Biochemistry from the Medical College of Wisconsin followed by postdoctoral training at Harvard Medical School and Boston Children's Hospital in molecular and cell biology. Dr. Sander Lee was an appointed faculty member at the Medical College of Wisconsin, where she directed a research laboratory investigating congenital heart disease in children and served as Scientific Director of Molecular Diagnostics at Children's Hospital of Wisconsin. She has also served as a scientific consultant and is currently a member of the U.S. Secretary of Health and Human Services Advisory Committee on Infant and Maternal Mortality.Dr. Sander Lee is dedicated to promoting ethical advancements in healthcare that protect the sanctity of every human life. She has given expert legislative testimony, numerous national media interviews, and provided scientific advice for legislators, policymakers, and organizations. Dr. Sander Lee is published in various medical journals and textbooks, including her most recent contribution to the book, Choose Life: Answering Support the show

Molecular diagnostics teams help physicians implement precision medicine that results in better outcomes for patients with a variety of conditions. Craig Mackinnon, M.D., director of the Division of Genomics Diagnostics and Bioinformatics, discusses how molecular pathologists work hand-in-hand with oncologists and pathologists to develop treatment strategies from patients' molecular profiles (i.e., identifying meaningful mutations). Learn how in-house molecular diagnostics labs allow institutions to deliver care more efficiently.

CENTOGENE's Prof. Peter Bauer and Dr. Jorge Pinto Basto join host Ben Legg to look back on 25 Years since the human genome project was concluded. Today, we are discussing the Human Genome Project – looking at the initial impact, the advancements in the past 20 years, and what the future of genetics and rare disease patient care could look like. Before joining CENTOGENE, Jorge served as the Director of the Molecular Diagnostics and Genomics Labs at CGC Genetics. He holds a medical degree from the University of Porto and is specialized in Rare Disease Genetics, Neurogenetics, Dysmorphology, and Molecular Genetics. Listen in as Dr. Basto and Prof. Bauer share their insights into their journey with genomic testing 25 years later.

Scientists continuously develop new assays to fill unmet diagnostic needs. While methods such as quantitative PCR have emerged as essential tools in molecular diagnostics, scientists developing and administering these assays still must overcome technical challenges. In this podcast series, The Scientist's Creative Services Team talks to experts about their experiences designing and implementing assays and protocols for future molecular diagnostics.   In this episode, Deanna MacNeil from The Scientist's Creative Services Team spoke with Ming-Sound Tsao, a senior scientist and clinician at Princess Margaret Cancer Centre, about considerations and variables for choosing appropriate assays in precision lung cancer treatment, including biomarkers, internal controls, test sensitivity, and specificity.   Welcome to Molecular Diagnostics: An Eye Toward the Future, a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Thermo Fisher Scientific, a world leader in serving science. Their mission is to enable customers to make the world healthier, cleaner, and safer. Whether their customers are accelerating life sciences research, solving complex analytical challenges, and improving clinical research workflows, Thermo Fisher Scientific is here to support them.

Scientists commonly use qPCR applications in molecular diagnostics to detect pathogens, assess viral loads, or uncover mutations. While the qPCR assay itself may seem straightforward, other aspects such as data collection and security, and following regulatory guidelines, present challenges. In part one of this episode, Gloria Lam, the associate director of qPCR software for Thermo Fisher Scientific, discusses concerns surrounding molecular diagnostic data collection, analysis, cybersecurity, and more.   Welcome to Molecular Diagnostics: An Eye Toward the Future, a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Thermo Fisher Scientific, a world leader in serving science. Their mission is to enable customers to make the world healthier, cleaner, and safer. Whether their customers are accelerating life sciences research, solving complex analytical challenges, and improving clinical research workflows, Thermo Fisher Scientific is here to support them. Scientists continuously develop new assays to fill unmet diagnostic needs. While methods such as quantitative PCR have emerged as essential tools in molecular diagnostics, scientists developing and administering these assays still must overcome technical challenges. In this podcast series, The Scientist's Creative Services Team talks to experts about their experiences designing and implementing assays and protocols for future molecular diagnostics.

Scientists commonly use qPCR applications in molecular diagnostics to detect pathogens, assess viral loads, or uncover mutations. While the qPCR assay itself may seem straightforward, other aspects such as data collection and security, and following regulatory guidelines, present challenges.   In part two of this episode, Fernando Beils, vice president and general manager of Thermo Fisher Scientific's qPCR Instruments, Assays, and Digital group, introduces an innovative software that streamlines molecular diagnostic testing by facilitating automation and connectivity in qPCR workflows.   Welcome to Molecular Diagnostics: An Eye Toward the Future, a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Thermo Fisher Scientific, a world leader in serving science. Their mission is to enable customers to make the world healthier, cleaner, and safer. Whether their customers are accelerating life sciences research, solving complex analytical challenges, and improving clinical research workflows, Thermo Fisher Scientific is here to support them. Scientists continuously develop new assays to fill unmet diagnostic needs. While methods such as quantitative PCR have emerged as essential tools in molecular diagnostics, scientists developing and administering these assays still must overcome technical challenges. In this podcast series, The Scientist's Creative Services Team talks to experts about their experiences designing and implementing assays and protocols for future molecular diagnostics.

In our latest update, we discuss the use of molecular techniques in the management of uveal melanoma with Dr. William Harbour, Professor and Chair, Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas.

Welcome to Molecular Diagnostics: An Eye Toward the Future, a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Thermo Fisher Scientific, a world leader in serving science. Their mission is to enable customers to make the world healthier, cleaner, and safer. Whether their customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing productivity in their laboratories, Thermo Fisher Scientific is here to support them. Scientists continuously develop new assays to fill unmet diagnostic needs. While methods such as quantitative PCR have emerged as essential tools in molecular diagnostics, scientists developing and administering these assays still must overcome technical challenges. In this podcast series, The Scientist's Creative Services Team talks to experts in assay development about their experiences designing and implementing assays and protocols for future molecular diagnostics. In this episode, Niki Spahich from The Scientist's Creative Ser vices Team spoke with Anne Wyllie, a research scientist in epidemiology at the Yale School of Public Health, about the development of SalivaDirect—a quantitative PCR protocol, authorized by the FDA under an emergency use authorization, that detects SARS-CoV-2 in saliva.  

Welcome to the Big Ideas Monday Miniseries, brought to you by the For Your Innovation Podcast. Big Ideas is meant to enlighten investors on the long-term impact of innovation. This annual research report seeks to highlight the technological breakthroughs evolving today and creating the potential for super-exponential growth tomorrow. We believe that innovation is taking off now, corroborating our original research and boosting our confidence that ARK's strategies are on the right side of change. To learn more, view Big Ideas 2023. This week's Big Ideas Monday Mini Episode focuses on Molecular Diagnostics. Next-generation sequencing (NGS) costs have collapsed, making molecular diagnostic tests more feasible and turbocharging our understanding of tumor biology.[1] By leveraging artificial intelligence (AI), cancer diagnostics labs have created less invasive tests like liquid biopsies to supplement tissue biopsies.[2] As proof of clinical utility accumulates, ARK estimates that the total addressable market (TAM) for molecular cancer diagnostic tests in the US is ~$95 billion, its revenue increasing more than 20% annually during the next five to ten years, from ~$5 billion in 2022 to $24 billion in 2030. Moreover, the collective enterprise value of molecular cancer testing companies should expand at a similar rate from ~$30 billion in 2022 to $145 billion in 2030. Wach the video version here.

In this podcast episode, MIDI Principal Greg Montalbano will discuss the various Point of Care and At Home Diagnostic testing technology applications covering the details of the science and value proposition for detection, market application, as well as global health. The technology platforms discussed in this episode include a host of Molecular Diagnostics, including: - CRISPR - RT-PCR - LAMP and others Listen to Episode 3 to learn more about the rapid acceleration and application of Point of Care and At Home diagnostic platforms. The wide adoption of these testing platforms, coupled with other advances in care, and the participation of companies providing laboratory-like services available directly to the home or clinic, represents a significant advance in the delivery of medical care. It represents a cultural shift likely to persist long after COVID‐19 becomes an endemic illness—as it should—because it offers a profound opportunity to improve the affordability, access, and effectiveness of medical care for a range of common diseases.

Drs. Pratik Patel, Kevin Messacar, and Robin Patel provide a primer on molecular diagnostics, from the basics of DNA and RNA to navigating PCR and metagenomic next generation sequencing. https://febrilepodcast.com/episodes/ (Episodes) |https://febrilepodcast.com/consult-notes/ ( Consult Notes) |https://febrilepodcast.captivate.fm/listen ( Subscribe) |https://twitter.com/febrilepodcast ( Twitter) |https://febrile.bigcartel.com/ ( Merch) | febrilepodcast@gmail.com

Dr. Matthew Hiemenz and Dr. Damon Olson discuss molecular testing practices for sarcomas to help differentiate between types

The identification of molecular subtypes of non-squamous NSCLC continues to grow, spurring the development of targeted therapies designed to target these mutations and prevent the growth of the cancer. People with advanced NSCLC that possess one of these ‘actionable' mutations and can access targeted treatments can live for many years with very manageable side effects. However, the technology to identify these actionable mutations in a single test and the targeted treatments are not yet accessible to all people with advanced NSCLC.In this TOGA podcast, we explore access to molecular diagnostics and treatments across ANZ: the past, present, future. Chaired by Professor Nick Pavlakis: Medical Oncologist, Royal North Shore Hospital, Genesis Care and Chair of Thoracic Oncology Group of Australasia ; joined by Dr Laird Cameron: Medical Oncologist Auckland Hospital and Canopy Cancer Care and TOGA Scientific Committee New Zealand representative and Dr Renuka Chittajallu, Medical Oncologist Riverina Cancer Care Centre, Griffith Base Hospital, Genesis cancer care, Kingswood, Director of Clinical Trials, Riverina Cancer Care Centre.In Australia, the TOGA ASPiRATION study is evaluating the impact of providing comprehensive genomic profiling and access to targeted therapies, with the hope that this will provide the evidence for widespread reimbursement for testing and treatments for patients where an actionable mutation is identified.https://thoraciconcology.org.au/aspiration/ 

Colorectal cancer is one of the leading causes of cancer death, but is remarkably treatable if caught early. Unfortunately, because of the invasive nature of the colonoscopy, many elect not to have this procedure done in a regular and timely manner. Colorectal cancers advance from normal cells through several distinct neoplasias, each with distinct patterns of gene expression. Today's guest is Dr. Erica Barnell from Geneoscopy.  They have devised a test to identify evidence of precancerous gene expression in the stool.  This advance makes early detection more feasible, along with a higher likelihood of frequent testing, at a significantly lower cost than outpatient procedures. Genoscopy Information:Website:     www.geneoscopy.comLinkedIn:     @GeneoscopyTwitter:        @GeneoscopyCo    Facebook:  @GeneoscopyCo

We all experienced the importance of at-home testing from the Covid19 pandemic and today's guest is helping bring rapid, affordable, and accurate tests to everyone including traditionally underserved areas.  Dive into how Domus Diagnostics got started, the importance of Nucleic Acid Testing, and getting started with clinical trials to get FDA clearance with Kelly and Paul on this episode of From Lab to Launch.About Paul ChapmanFrom sales representative to CEO, Board Member and Angel Investor, Paul Chapman has over 25 years of international business leadership experience in Molecular Diagnostics, Point of Care Diagnostics, Medical Devices and Life Sciences. He is skilled at change agent and is a creative, action-oriented leader with a broad base of international Diagnostic, Medical Device and Life Sciences executive experience.  Whether creating a new business or optimizing existing business models, Paul has created significant value by focusing on development of a high-performance culture through professional "A+" teams that he helps build.About Domus DiagnosticsDomus Diagnostics  seeks to create tests for infectious diseases that are affordable, user-friendly, accurate, and rapid enough to address the needs raised by current and future public health crises. All this not only in the US but in every global market including underserved areas - talk about a big vision! LinksDomus Diagnostics: https://www.domusdx.com/ Paul's LinkedIn:  https://www.linkedin.com/in/paul-chapman-7b44508/Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez 

Dr. Tara Sander Lee with the Charlotte Lozier Institute weighs in on the recent Supreme Court decision and shares the latest on life-related research, public policy, and media. Dr. Lee also shares resources for those facing an unplanned pregnancy.  Tara Sander Lee, Ph.D. is the Senior Fellow and Director of Life Sciences at the Charlotte Lozier Institute, an organization dedicated to policies and practices that protect the sanctity of human life. She is a scientist with 20 years of experience in academic and clinical medicine with an emphasis on the cause of pediatric disease. She obtained a Ph.D. in Biochemistry from the Medical College of Wisconsin and fellowship training at Harvard Medical School and Boston Children's Hospital. Dr. Sander Lee was an appointed faculty member at the Medical College of Wisconsin for over 15 years, where she directed a research lab investigating congenital heart disease in children and served as Scientific Director of Molecular Diagnostics at Children's Hospital of Wisconsin. Dr. Sander Lee is published in various medical journals and textbooks, including her recent co-authored manuscript in the journal Issues in Law and Medicine, “The Perinatal Revolution”. Dr. Sander Lee is dedicated to promoting ethical advancements in healthcare and protecting human life, with special emphasis on perinatal and early postnatal periods. She has been invited to speak, give expert testimony, and provide scientific advice for several legislators, policymakers, and organizations. She has published op-eds and been interviewed by local and national media outlets. See omnystudio.com/listener for privacy information.

Dr. Grody specializes in Medical Genetics & Molecular Diagnostics. Let's talk about their journey and the lessons learned over their 33 years of practice.

At some point, most of us encounter a life-altering medical condition. Either our own or someone around us. When you come face-to-face with Alzheimer's, Parkinsons, HIV, cancer, or any of the serious conditions the human body can fall victim to, it's not uncommon to find yourself asking, “Why haven't they found a cure for this yet?” And to hope that somebody, somewhere, right now, is working on a cure. The questions you probably don't think about, are, who exactly are “they” who haven't found a cure for this. And who exactly is the “somebody somewhere” who is hopefully unravelling the science of disease. Well, two of those people are Peter's guests on this edition of Out to Lunch.  Dr. Chenzhong Li is a world-renowned scientist. He's an inventor of breakthrough medical technology in the fields of Alzheimer's, cancer, and infectious diseases. Dr. Li is the holder of 18 medical patents, including for the diagnosis and treatment of Alzheimer's and certain types of cancer. He's a member of a very prestigious body of medical professionals, the National Academy of Inventors. And Dr Li is a Professor at the Center for Cellular and Molecular Diagnostics at Tulane University. If you're thinking it's extraordinary that somebody of Dr Li's stature is working in a lab in downtown New Orleans, wait till you hear what's going on in Thibodaux. Thibodaux is home to a company called BioInfo Experts. BioInfo Experts is a tech company that works on a branch of science called pathogen genomics. They sequence the genomes of infectious diseases. Then they use computational analytical tools to improve the identification, tracking, and treatment of infections. It's part biology, part computational science, and part statistical analysis. The founder and CEO of BioInfo Experts is Susanna Lamers. Susanna started out working in a lab in Florida back in the days of the AIDs epidemic and pioneered the science of collating disease data and turning it into digital tables. She turned those skills into a business and relocated to Thibodaux to run it remotely long before the next major US epidemic was going to turn remote work into a commonplace modus operandi. Anyone who lives in New Orleans can tell you, the city we live in is vastly different from the impression you get of the place from the outside. Sure, local New Orleanians enjoy Mardi Gras and music festivals, and we might even occasionally wander around the French Quarter with a cocktail. But beneath the fun exterior, there's a city of business, industry, and science that's equal to just about any place you could name. Out to Lunch is recorded live over lunch at NOLA Pizza in the NOLA Brewing Taproom. You can find photos from this show by Jill Lafleur at itsneworleans.com. And check out more lunchtime conversation about breakthrough science from right here in New Orleans. See omnystudio.com/listener for privacy information.

Dr. Tara Sander Lee joins Dawn and Steve Mornings to share what 20 years as a biochemist has taught her about LIFE! Tara Sander Lee, Ph.D. is the Senior Fellow and Director of Life Sciences at the Charlotte Lozier Institute, an organization dedicated to policies and practices that protect the sanctity of human life. She is a scientist with 20 years of experience in academic and clinical medicine with an emphasis on the cause of pediatric disease. She obtained a Ph.D. in Biochemistry from the Medical College of Wisconsin and fellowship training at Harvard Medical School and Boston Children's Hospital. Dr. Sander Lee was an appointed faculty member at the Medical College of Wisconsin for over 15 years, where she directed a research lab investigating congenital heart disease in children and served as Scientific Director of Molecular Diagnostics at Children's Hospital of Wisconsin. Dr. Sander Lee is published in various medical journals and textbooks, including her recent co-authored manuscript in the journal Issues in Law and Medicine, “The Perinatal Revolution”. Dr. Sander Lee is dedicated to promoting ethical advancements in healthcare and protecting human life, with special emphasis on perinatal and early postnatal periods. She has been invited to speak, give expert testimony, and provide scientific advice for several legislators, policymakers, and organizations. See omnystudio.com/listener for privacy information.

On this episode of The Power of Love Show we welcome back friend of DDJF & CEO of OncoCyte, Mr. Ronnie Andrews. Ronnie has close to 30 years of experience in the Global Clinical and Molecular Diagnostics industry and joined us in the last for 2 very informative episodes on the topic of Covid-19 back in September & December of 2020. On this episode, Ronnie joins us to share a helpful & accurate update as we continue to navigate the news surrounding COvID-19, the vaccines and the booster shots. Show Sponsors: * 4space * The Dime - LA * Shaved LA * Over Under Public House * Food Cart Party Subscribe to our YouTube channel: https://www.youtube.com/watch?v=2-Nd1HTnbaI Like Our Facebook Page: https://www.facebook.com/884355188308946/ Have you subscribed to our Podcast? Apple Podcasts: https://podcasts.apple.com/fr/podcast/the-power-of-love-show/id1282931846 Spotify Podcasts : https://open.spotify.com/show/6X6zGAPmdReRrlLO0NW4n6?si=bhNl9GjJRxKXUvTdwZme6Q Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly9wb3dlcm9mbG92ZS5saWJzeW4uY29tL3Jzcw Other podcasts: https://anchor.fm/thepowerofloveshow Did you know you can support DDJF through any of your Amazon purchases? Simply click link below and select Dee Dee Jackson Foundation as your charity of choice: https://smile.amazon.com/gp/chpf/dashboard/ref=smi_nav_surl_mi_x_mkt Once done… bookmark and use your smile link to support DDJF! The Power of Love Show is a weekly show sponsored by The Dee Dee Jackson Foundation where we shine a light on loss and grief and how it impacts our lives. Our aim is to build a community where we share inspiring stories, interview experts, learn, grow and empower one another to find proper and healthy healing. Visit the DDJF official website: http://www.ddjf.org/ Donate to DDJF (501c3): https://app.mobilecause.com/form/xDJ0Cg?vid=74qmm Check Out DDJF Merch: https://teespring.com/.../collection/All%20Products... Join the Dee Dee Jackson Facebook Group https://www.facebook.com/groups/1500933326745571 Follow us on Instagram: @DeeDeeJacksonFoundation • https://instagram.com/deedeejacksonfoundation?utm_medium=copy_link --- Support this podcast: https://anchor.fm/thepowerofloveshow/support

Take a virtual lab tour and learn more about the significance of the UC Santa Cruz Molecular Diagnostic Lab (MDL) to our community and how testing works at UC Santa Cruz. The MDL has been open since May 2020, working to increase area SARS-CoV-2 testing capacity in order to contribute to a pandemic exit strategy. Series: "UCTV Prime" [Health and Medicine] [Show ID: 37471]

Take a virtual lab tour and learn more about the significance of the UC Santa Cruz Molecular Diagnostic Lab (MDL) to our community and how testing works at UC Santa Cruz. The MDL has been open since May 2020, working to increase area SARS-CoV-2 testing capacity in order to contribute to a pandemic exit strategy. Series: "UCTV Prime" [Health and Medicine] [Show ID: 37471]

Take a virtual lab tour and learn more about the significance of the UC Santa Cruz Molecular Diagnostic Lab (MDL) to our community and how testing works at UC Santa Cruz. The MDL has been open since May 2020, working to increase area SARS-CoV-2 testing capacity in order to contribute to a pandemic exit strategy. Series: "UCTV Prime" [Health and Medicine] [Show ID: 37471]

Take a virtual lab tour and learn more about the significance of the UC Santa Cruz Molecular Diagnostic Lab (MDL) to our community and how testing works at UC Santa Cruz. The MDL has been open since May 2020, working to increase area SARS-CoV-2 testing capacity in order to contribute to a pandemic exit strategy. Series: "UCTV Prime" [Health and Medicine] [Show ID: 37471]

Take a virtual lab tour and learn more about the significance of the UC Santa Cruz Molecular Diagnostic Lab (MDL) to our community and how testing works at UC Santa Cruz. The MDL has been open since May 2020, working to increase area SARS-CoV-2 testing capacity in order to contribute to a pandemic exit strategy. Series: "UCTV Prime" [Health and Medicine] [Show ID: 37471]

Take a virtual lab tour and learn more about the significance of the UC Santa Cruz Molecular Diagnostic Lab (MDL) to our community and how testing works at UC Santa Cruz. The MDL has been open since May 2020, working to increase area SARS-CoV-2 testing capacity in order to contribute to a pandemic exit strategy. Series: "UCTV Prime" [Health and Medicine] [Show ID: 37471]

The computing world has come a long way in less than 100 years. Since Alan Turing introduced his paper ‘Computing Machinery and Intelligence' in 1950, we have not only achieved the ‘Turing Test' of Artificial Intelligence, but exceeded it. This episode takes a look at Digital Pathology and the prospects of Artificial Intelligence particularly in relation to Anatomical Pathology. Our special guest is Dr Joseph Anderson Dr Joseph Anderson Bio Connect on LinkedIn  Dr. Joseph Anderson, the host of Digital Pathology Today, is a consultant to early stage and mature companies in the digital pathology and molecular diagnostics space. Previously, he oversaw the clinical pathology group at Genomic Health as the Oncotype Dx Breast Cancer Assay grew to a volume of over half a million tests. He was also involved in the development of new products, including assays for DCIS, Colon Cancer and one of the first commercially available liquid biopsies. He served the College of American Pathologists on the Molecular Oncology Committee, with responsibility for proficiency testing in biomarkers for lung cancer in the United States and across the world and as a member of the House of Delegates representing the State of California. He has served on several working groups and committees for the American Medical Association for CPT coding and reimbursement and assessment of new technologies such as next generation sequencing. Upon graduating from the University of Minnesota Medical School, Dr. Anderson completed residency in Anatomic and Clinical Pathology at Rush University, fellowship in Oncologic Pathology at Fox Chase Cancer Center and post-doctoral training in Molecular Diagnostics at UCSF. He initially worked in private practice, credentialed at 17 various hospitals and surgery centers. Digital pathology Today Link: https://www.digitalpathologytoday.com Digital Pathology Today™ is your podcast all about the world of digital pathology.      See omnystudio.com/listener for privacy information.

** Thanks for downloading this episode. If you'd like to stay in touch with our continuing story, Season 2 continues at This Medical Life, in which Dr Travis Brown continues his exploration of diseases and our approaches to treatment from history to the modern day. Have a look in your podcast app now for This Medical Life, and hit subscribe so you never miss an episode ** The computing world has come a long way in less than 100 years. Since Alan Turing introduced his paper ‘Computing Machinery and Intelligence' in 1950, we have not only achieved the ‘Turing Test' of Artificial Intelligence, but exceeded it. This episode takes a look at Digital Pathology and the prospects of Artificial Intelligence particularly in relation to Anatomical Pathology. Our special guest is Dr Joseph Anderson   Dr Joseph Anderson BioConnect on LinkedIn  Dr. Joseph Anderson, the host of Digital Pathology Today, is a consultant to early stage and mature companies in the digital pathology and molecular diagnostics space.Previously, he oversaw the clinical pathology group at Genomic Health as the Oncotype Dx Breast Cancer Assay grew to a volume of over half a million tests. He was also involved in the development of new products, including assays for DCIS, Colon Cancer and one of the first commercially available liquid biopsies.He served the College of American Pathologists on the Molecular Oncology Committee, with responsibility for proficiency testing in biomarkers for lung cancer in the United States and across the world and as a member of the House of Delegates representing the State of California. He has served on several working groups and committees for the American Medical Association for CPT coding and reimbursement and assessment of new technologies such as next generation sequencing.Upon graduating from the University of Minnesota Medical School, Dr. Anderson completed residency in Anatomic and Clinical Pathology at Rush University, fellowship in Oncologic Pathology at Fox Chase Cancer Center and post-doctoral training in Molecular Diagnostics at UCSF. He initially worked in private practice, credentialed at 17 various hospitals and surgery centers. Digital pathology Today Link: https://www.digitalpathologytoday.comDigital Pathology Today™ is your podcast all about the world of digital pathology.   See omnystudio.com/listener for privacy information.

Join us for a conversation between the Medical Alley Association's Alexis Kochanski and Kaliah Linear and Vildan Kehr of Abbott. Vildan is Abbott's Divisional Vice President of Human Resources for Rapid and Molecular Diagnostics. Kaliah is a recent high school graduate who also spent two years as an Abbott STEM intern. They both share more about Abbott's STEM internship program, which now offers students the ability to earn college credit.

In this episode, we spoke to Jonathan O'Halloran, Founder and CEO at QuantumDX, a molecular diagnostics technology company based in the North-East. We talked to Jonathan about his journey from academia to business, his travels around the world working on diagnostics for Tuberculosis (TB), and the challenges that come with quickly scaling production of a product in the face of huge demand.

Marcelo Trevnio, the VP of Regulatory & Quality at Agendia has built a storied career for himself. He earned his Bachelors Degree in Industrial & Systems Engineer and a Masters Degree in Business Administration. Marcelo also has his Certification in Regulatory Affairs Management and he is a Master Medical Device Auditor through Exemplar Global and is also known as a Biomedical Auditor through ASQ. Over the years, Marcelo has worked his way up the ladder holding various progressive leadership roles at organizations like Medtronic, Nihon Kohden, Applied Medical, and now Agendia.Agendia is the only Molecular Diagnostics company focused solely on breast cancer. The organization uses groundbreaking genomic testing to generate reliable and meaningful clinical data about the unique biology of a woman's breast cancer.During our conversation, Marcelo and I discuss pivotal moments and experiences during his own career journey to-date that helped him achieve his level of success. We also discuss what he looks for when building high performing teams, and several recommendations he has to those aspiring to climb the rungs of leadership themselves.Marcelo Trevino on LinkedIn:https://www.linkedin.com/in/marcelo-trevino-0015921/Agendia:https://agendia.com/

Today my guest is Dr Joseph Anderson, Pathologist and host of the Digital Pathology Today podcast. What we discuss with Dr Anderson : How he became interested in pathology His fellowship in Oncologic Pathology His post doctoral fellowship in Molecular Diagnostics His work with Oncotype testing The Personalized Diagnostics podcast The Digital Pathology Today podcast and how it began What the future of digital pathology might be Links for this episode: Health Podcast Network  LabVine Learning The ConfLab from LabVine Dress A Med scrubs   Digital Pathology Today: Website Twitter Personalized Diagnostics Podcast Oncotype   People of Pathology Podcast: Website Twitter

 Co-host Tywauna Wilson sat down to talk with Lindsey Clark, MPH, MLS (ASCP) about Laboratory Professional Credentialing & The Importance of Forming a Professional Identity.Medical laboratory science is often referred to as the hidden profession. Many healthcare professionals working in the same hospital as laboratory professionals do not fully understand what we do, so can we really expect that from patients, the public, the media, and politicians? One major reason for the lack of understanding is the absence of a cohesive professional identity among laboratory professionals. Lindsey talks about how there are many credentialing agencies and job titles out there today, and discuss the importance of forming a more unified professional identity. Several national organizations are working towards more standardized certifications and job titles to help decrease confusion within and outside of the field. We ended the interview with detailing those efforts and making suggestions for how laboratory professionals can help promote and advocate for the profession no matter what their role.Guest Bio:Lindsey Clark is an Assistant Professor in the Department of Laboratory Sciences at UAMS in Little Rock, Arkansas. She teaches Current Topics in Medical Laboratory Sciences and Molecular Diagnostics to both traditional MLS and MLT-to-MLS distance students. Lindsey is heavily involved in Interprofessional Education at UAMS, where she advocates for laboratory science students and professionals to play a larger role in interprofessional teams. Her research interests include biological and laboratory safety, virtual reality training, and interprofessional education for lab science students. She also works to promote the profession on social media and you can find her on Twitter, Instagram, and Facebook under @LindseyInTheLab.Be a Supporter!Listen on Spotify, Apple Podcasts or your favorite podcast platformDon't forget to subscribe to the show on your phone, tablet or notebook so you never miss an episode!Be sure to leave a comment, and share with a fellow medical laboratory professionals!Be a Guest!If you have a leadership or laboratory message to share and would like to be a guest on the show, please reach out to us at elaboratetopics@directimpactbroadcasting.com, Direct Impact Broadcasting on Social Media, or complete the Guest Interest Form.  

https://pir.sa.gov.au/research/research_specialties/crop_sciences/soil_biology_and_molecular_diagnostics (Dr. Alan McKay) joins us all the way from Australia, to talk about some exciting work they are doing to measure various soil microbes including pathogens and beneficial rhizobia.  Dr McKay is the Leader of the Soil Biology and Molecular Diagnostics group at the https://pir.sa.gov.au/research (South Australian Research and Development Institute) (SARDI). He is committed to not only studying soil-borne diseases and other aspects of soil biology, but also developing tools for growers to manage this biology in their operations. He has played a major role in the development of the https://pir.sa.gov.au/research/services/molecular_diagnostics/predicta_b (PREDICTA® B) soil analysis technology, which is now recognised internationally for its capacity to accurately identify and measure soil pathogens, as well as the nutrition status of soils. We're going to talk a lot more about this technology in today's episode. “The thing we're doing now with the https://pir.sa.gov.au/research/services/molecular_diagnostics/predicta_b (PREDICTA® B) technology is starting to look at some of the beneficial organisms. So rhizobium for pulses...which is the rhizobia that modulate lentils, field pea and fava bean. Then using that we launched it as a provisional service just in South Australia and Victoria this year to identify paddocks where you don't need to inoculate the pulse crop. In Australia, the growers don't like applying their innoculates to the pulse crops. Most reliable methods have to be done just before seeding them and it's a task they prefer not to do. So we think this is going to work pretty well.” - Dr. Alan McKay After sampling 850 paddocks they have identified 400 species to allow his group to map the growth of pathogens across the country. One unexpected discovery was that prior to this survey it was assumed there was one Phytophthora species with the potential for causing major harm to pulse crops. Now they have identified three separate species and can better isolate their locality and the tools to better identify them. At the moment, they are focusing on identifying more common pathogens going forward that, while not as catastrophic as Phtyophtora, can reduce yield by up to 20% and are therefore also significant. “https://pir.sa.gov.au/research/services/molecular_diagnostics/predicta_b (PREDICTA® B) is a collection of what we call qPCR tests.” Dr McKay remarks that it is easy to quality control, scalable and offers great insight for growers and researchers alike. Currently the majority of their testing has focused on cereal crops but they are readily expanding into pulse crops. “The potential now with pulses is that we could look at packaging tests for key pathogens and the rhizobium and identify whether a paddock is a good option for that crop and whether you need to inoculate.” - Dr. McKay This Week on https://www.growingpulsecrops.com/ (Growing Pulse Crops): Meet https://pir.sa.gov.au/research/research_specialties/crop_sciences/soil_biology_and_molecular_diagnostics (Dr. Alan McKay) the Leader of the Soil Biology and Molecular Diagnostics group at the https://pir.sa.gov.au/research (South Australian Research and Development Institute) (SARDI). Discover the progress his efforts and research are accomplishing in supporting pulse growers in Australia using DNA technologies like https://pir.sa.gov.au/research/services/molecular_diagnostics/predicta_b (PREDICTA® B) Learn the benefits to this line of technology and the advantages it can provide to producers in inputs, variety selection and for monitoring of pathogen spread Growing Pulse Crops Podcast is hosted by https://www.linkedin.com/in/timhammerich/ (Tim Hammerich) of the http://www.futureofag.com (Future of Agriculture Podcast).

Lawrence is the President of SiO2 Materials Science, a company focused on three core segments: Pharmaceuticals, Molecular Diagnostics, and Consumer Healthcare. Given a $143 million investment grant from the U.S. government, SiO2 is on a mission to tackle the vaccine vial shortage. They hold over 300 patents and are known for their unique glass like barrier for application onto any plastic surface so as to increase its durability. Throughout the Covid Crisis, demand for this material has surged, presenting a novel opportunity for SiO2. To date, they have supplied vials for over 100 million Covid vaccine doses. Lawrence holds a Bachelors of Science in Entrepreneurship from Babson College and was previously the CEO of Innoplexus. Lawrence joins us to discuss the products that SiO2 offer, how SiO2 scaled during Covid, and trends in the Materials Science space. https://www.sio2ms.com/

Released March 2021. Science, technology, and match are miraculous tools, and many who enter the field of STEM are driven to figure out how our universe works. Lambert Wilson is a Research And Teaching Assistant at The University of Winnipeg and has studied in Ghana, Italy, and Canada. Lambert is a Strong professional with a Master's degree focused on Molecular Diagnostics and Biotechnology. Music: Sergey Borovkov - Space Battlestar Galaxy by Tunguska Electronic Music Society.

Join Kristin and Dr. Vigerust discussing the vaccination process and the new phases of our pandemic experiences.Dr. Vigerust received a bachelor’s degree in Biology and Chemistry from the University of Texas at El Paso, a master’s degree in Microbiology and Immunology from Texas Tech University and a Doctorate in Cellular and Molecular Pathology from Vanderbilt University School of Medicine. Dr. Vigerust conducted post-doctoral research at St. Jude Children's Research Hospital. Dr. Vigerust completed a second post-doctoral fellowship at Vanderbilt University Medical School in the Department of Pediatrics Disease in the area of molecular biology. Currently, Dr. Vigerust is completing a second master’s degree in Molecular Diagnostics from Arizona State University.Dr. Vigerust was a faculty member in the Pathology, Immunology and Microbiology Department at Vanderbilt University School of Medicine and a Health Research Scientist in the U.S. Department of Veteran’s Affairs. Most recently, Dr. Vigerust is the Chief Scientific Officer and molecular scientist for several diagnostics laboratories focused around precision medicine, genomics and infectious disease. Dr. Vigerust has published extensively in top tier international journals, presented his research at national and international conferences and is an active editor and reviewer for several prominent journals. Dr. Vigerust has developed several novel molecular diagnostic assays for the prediction of inflammation and cardiovascular risk in patients with diabetes, infectious disease and cancer. Dr. Vigerust speaks often on the subject of precision medicine and was selected as a TEDx speaker in 2016. He serves on the scientific advisory boards of Proze, Electronic Care Giver and ImAware.Dr. Vigerust currently maintains an Adjunct Assistant Professor position at Vanderbilt University Medical Center in the Department of Neurological Surgery and a Clinical Assistant Professor position with the University of Maryland, Eastern Shore School of Pharmacy. Dr. Vigerust’s academic and research interests focus around areas of precision medicine in the treatment of a broad range of disorders that are driven by inflammation including psychiatric and behavioral disorders, pain, neurooncology and cardiovascular disease.

Join host Blake Adams and Spesana's Founder and CEO Carla Balch in a discussion about the trends and technologies improving collaboration in molecular diagnostics.

Molecular diagnostics are emerging as a precise way to detect diseases early on in prognosis. In today's episode, I chat with Harvard+MIT PhD Student Ava Soleimany on the role of data science in activity-based molecular diagnostics for early cancer detection and how the confluence of classification techniques with feature representation of cancer biomarkers can enable non-invasive, early detection. Check out the glossary of terms, definitions, and resources (and get a sneak peak of the future conversations lined up!) here: bit.ly/datapulse-glossary --- Support this podcast: https://anchor.fm/the-data-pulse/support

Learn about the importance of laboratory testing in the identification of a C. difficile Infection (CDI). with guests: Jeanine Thomas, President and Founder of the MRSA Survivors Network who is a survivor of both MRSA and C. diff. infections. Dr. Nathan A. Ledeboer, PhD, D(ABMM), Medical Director of Microbiology and Molecular Diagnostics for Wisconsin Diagnostic Laboratories and Froedtert Health. Dr. Whitney R. Buckel, PharmD, BCPS who is the Infectious Diseases and Antimicrobial Stewardship Clinical Pharmacist at Intermountain Medical Center, and Dr. Steven Cagas, who will give us a brief overview of Roche Diagnostics as well as their new cobas® Cdiff Test.

Learn about the importance of laboratory testing in the identification of a C. difficile Infection (CDI). with guests: Jeanine Thomas, President and Founder of the MRSA Survivors Network who is a survivor of both MRSA and C. diff. infections. Dr. Nathan A. Ledeboer, PhD, D(ABMM), Medical Director of Microbiology and Molecular Diagnostics for Wisconsin Diagnostic Laboratories and Froedtert Health. Dr. Whitney R. Buckel, PharmD, BCPS who is the Infectious Diseases and Antimicrobial Stewardship Clinical Pharmacist at Intermountain Medical Center, and Dr. Steven Cagas, who will give us a brief overview of Roche Diagnostics as well as their new cobas® Cdiff Test.

Learn about the importance of laboratory testing in the identification of a C. difficile Infection (CDI). with guests: Jeanine Thomas, President and Founder of the MRSA Survivors Network who is a survivor of both MRSA and C. diff. infections. Dr. Nathan A. Ledeboer, PhD, D(ABMM), Medical Director of Microbiology and Molecular Diagnostics for Wisconsin Diagnostic Laboratories and Froedtert Health. Dr. Whitney R. Buckel, PharmD, BCPS who is the Infectious Diseases and Antimicrobial Stewardship Clinical Pharmacist at Intermountain Medical Center, and Dr. Steven Cagas, who will give us a brief overview of Roche Diagnostics as well as their new cobas® Cdiff Test.